Tirzepatide versus dulaglutide Among patients in the expanded population who initiated tirzepatide or dulaglutide, the 1-year risk for the primary endpoint including all-cause mortality in the tirzepatide group was 1.4% (95% CI 1.3% to 1.6%) versus 1.8% (95% CI 1.5% to 2.0%) for dulaglutide
35 The FTC and some legal analysts argue that patents covering mechanical components like springs and gears should not be listed unless they specifically claim the drug substance or a method of use
, , 4-6 , , , , , , (31,4%)
In recent years, significant progress has been made in understanding how the gut microbiome impacts cardiovascular function and the development of these diseases
KPV reduces the inflammatory signaling from chronic hyperglycemia that drives ongoing nerve injury
Our GLP-1 mass tort lawyers discuss how gallbladder removal after these drugs can form the basis of a product liability claim, what medical documentation courts look for, and how patients can preserve their right to compensation with early, evidence-driven representation